CT327 Phase IIb Psoriasis Study

• Research type

  Research Study

• Full title

  A Randomized, Placebo-controlled Phase IIb Study to Evaluate the Efficacy, Safety and Tolerability of 0.05%, 0.1% and 0.5% w/w topical CT327 when Applied Twice Daily in Subjects with Psoriasis Vulgaris.

• IRAS ID

  92803

• Contact name

  John Robinson

• Sponsor organisation

  Creabilis Limited

• Eudract number

  2011-004640-21

• ISRCTN Number

  N/A

• Research summary

  CT327 is a new topical ointment being developed for the treatment of psoriasis vulgaris. Study CT327-2003 will investigate the safety and effectiveness of three different strengths of CT327 ointment (0.05 %, 0.1% and 0.5%), compared to a placebo, in treating psoriasis vulgaris. Treatment will be applied twice daily, to psoriatic plaques, for up to 8 weeks.

• REC name

  London - South East Research Ethics Committee

• REC reference

  12/LO/0054

• Date of REC Opinion

  13 Feb 2012

• REC opinion

  Further Information Favourable Opinion